Ex-drug
executive Shkreli congratulates Australian students
Send a link to a friend
[December 02, 2016]
(Reuters) - Former pharmaceutical
executive Martin Shkreli has congratulated a group of Australian
students who reproduced the active ingredient for a life-saving,
anti-parasitic drug at the center of a drug-price controversy involving
his former company.
|
The students from Sydney Grammar School drew global media attention
this week after they said they had produced the drug Daraprim for
about $2 a dose, a fraction of the current list price of $750 per
dose.
Shkreli is a former chief executive of Turing Pharmaceuticals, where
he sparked outrage among patients and U.S. lawmakers for raising the
price of Daraprim by more than 5,000 percent.
"These Australian students are proof that the 21st century economy
will solve problems of human suffering through science and
technology," Shkreli said in a video message posted on YouTube.
"We should congratulate these students for their interest in
chemistry and I’ll be excited about what is to come in this
STEM-focused 21st century,” he said, referring to science,
technology, engineering and mathematics.
![](http://archives.lincolndailynews.com/2016/Dec/02/images/ads/current/flossies_sda_CHRISTMAS_2016.png)
Daraprim is used to fight parasitic infections in AIDS patients,
pregnant women and others.
The six students and their science teacher worked under the guidance
of the University of Sydney and members of the Open Source Malaria
consortium, which allows scientists to share research on
anti-malaria drugs.
"We had to repeat a lot of the reactions and try different reaction
conditions in order to see which materials in which things would
react to make the Daraprim," student Brandon Lee told Reuters
Television on Friday.
Turing made front-page headlines after it bought the rights to
Daraprim in August 2015. With no rival manufacturers making the
drug, Turing quickly raised the price for a tablet of Daraprim to
$750 from $13.50.
[to top of second column] |
![](http://archives.lincolndailynews.com/2016/Dec/02/images/ads/current/atlantabank_lda_CHRISTMAS_2016.png)
Overnight, the tiny company was vilified as an example of
pharmaceutical industry greed, drawing fire from politicians and
medical groups. Turing later said it would cut the cost of the drug
to hospitals.
Lee said the students wanted to show that "these compounds which you
think are only accessible to these large, large-scale companies are
actually able to be accessed and produced by ordinary citizens".
Shkreli stepped down as Turing's chief executive in December 2015
after being indicted on charges that he engaged in a Ponzi-like
scheme at a hedge fund and Retrophin Inc, a company he once headed.
He has pleaded not guilty.
(Reporting by Reuters Television; Writing by Darren Schuettler;
Editing by Robert Birsel)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2016/Dec/02/images/ads/current/lincolntheatre_sda_031016.png)
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/directory_buttons.png) |